Sofosbuvir Intermediate CAS 21382-82-1 Purity ≥98.0% (HPLC)

Short Description:

2-(triphenyl-phosphanylidene)-propionic acid ethyl ester

CAS: 21382-82-1

Appearance: Yellow Powder

Purity: ≥98.0% (HPLC) 

Intermediate of Sofosbuvir (CAS: 1190307-88-0) in the treatment of Hepatitis C Virus (HCV) 

Contact: Dr. Alvin Huang

Mobile/Wechat/WhatsApp: +86-15026746401

E-Mail: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Sofosbuvir Related Intermediates:

21382-82-1 - Chemical Properties:

Name 2-(triphenyl-phosphanylidene)-propionic acid ethyl ester
Synonyms triphenyl(1-[ethoxycarbonyl]ethylidene)phosphorane; ethyl 2-(triphenylphosphoranylidene)propanoate
CAS Number 21382-82-1
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C23H23O2P
Molecular Weight 362.41
Brand Ruifu Chemical

21382-82-1 - Specifications:

Item Specifications Results 
Appearance Yellow Powder Yellow Powder
Purity / Analysis Method ≥98.0% (HPLC) 98.5% 
Loss on Drying ≤1.00% (60℃, 2h) 0.39% 
Sum of PH3P+PH3PO ≤2.00% (HPLC) Conforms 
Unspecified Related Substances ≤0.50% (HPLC)   Conforms 
Test Standard Enterprise Standard Conforms 
Application Intermediate of Sofosbuvir (CAS: 1190307-88-0) 

Package & Storage:

Package: Bottle, Aluminum foil bag, 25kg/Drum, or according to customer's requirement 

Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture 

Advantages:

1

FAQ:

www.ruifuchem.com

21382-82-1 - Application:

Manufacturer with High Purity and Stable Quality
Commercial Supply Sofosbuvir (CAS: 1190307-88-0) and Related Intermediates: 
Sofosbuvir CAS: 1190307-88-0 
N4-Benzoylcytosine CAS: 26661-13-2
triphenyl(1-[ethoxycarbonyl]ethylidene)phosphorane CAS: 21382-82-1
L-Alanine Isopropyl Ester Hydrochloride CAS: 62062-65-1 
Pentafluorophenol CAS: 771-61-9 
N-[(S)-(2,3,4,5,6-pentafluorophenoxy)phenoxyphosphinyl]-L-alanine 1-Methylethyl ester CAS: 1334513-02-8

Sofosbuvir is a drug used for the treatment of hepatitis C. It is recommended to be used in combination with other drugs (such as velpatasvir) for the first-line treatment for HCV genotypes 1, 2, 3, 4, 5, and 6. It takes effect through acting as a nucleotide analog inhibitor, being capable of specially inhibiting the HCV NS5B (non-structural protein 5B) RNA-dependent RNA polymerase.  

  • Write your message here and send it to us